26. Rick factors associated with pulmonary arterial hypertension in systemic sclerosis
Main Article Content
Abstract
Pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc) is a lethal complication affecting 26% of patients. The cross-sectional study was conducted to determine rick factors associated with pulmonary arterial hypertension in systemic sclerosis. Among 50 patients with SSc - PAH and 25 patients with SSc - nonPAH at Center of Allergy and Clinical Immunology, Bach Mai hospital for 1 year (from June 2017 to June 2018). The result showed, age from 20 to 40 and anti RNP positive increase rick of PAH with odds ratio 5.4 (95%CI: 1.14 - 25.81) and 9 (95%CI: 1.01 - 80.1), respectively. NT-proBNP and Rodnan score were independent rick factors that associated pulmonary arterial hypertesion in systemic sclerosis. An increase of 1 poin in Rodnan score was associated with a 1.039 times higher in rick of PAH and an increase of 1 pmo/L in NT-proBNP was associated with a 1.079 times higher in rick of PAH, correct prediction percentage was 80.7%.
Article Details
Keywords
Systemic sclerosis, Pulmonary arterial hypertension, NT-proBNP, rick factor, Rodnan score
References
2. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Annals of the rheumatic diseases. 2010;69(10):1809-1815.
3. Proudman SM, Stevens WM, Sahhar J, et al. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Internal Medicine Journal. 2007;37(7):485-494. doi:10.1111/j.1445-5994. 2007.01370.x
4. Hachulla E, Launay D, Clerson P, et al. Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis? Chest. 2010;138(2):462-463.
5. Shah AA, Wigley FM, Hummers LK. Telangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension. The Journal of rheumatology. 2010;37(1):98-104.
6. Coghlan JG, Denton CP, Grünig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Annals of the rheumatic diseases. 2014;73(7):1340-1349.
7. Iudici M, Codullo V, Giuggioli D, et al. Pulmonary hypertension in systemic sclerosis: prevalence, incidence and predictive factors in a large multicentric Italian cohort. Clin Exp Rheumatol. 2013;31(2 Suppl 76):31-36.
8. Hinchcliff M, Varga J. Managing systemic sclerosis and its complications. The Journal of Musculoskeletal Medicine. 2011;28(10):380.
9. Diab S, Dostrovsky N, Hudson M, et al. Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects. The Journal of rheumatology. 2014;41(11):2179-2185.
10. Schneeberger D, Tyndall A, Kay J, et al. Systemic sclerosis without antinuclear antibodies or Raynaud’s phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database. Rheumatology. 2013;52(3):560-567.
11. Alhajeri H, Hudson M, Fritzler M, et al. 2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis Outperform the 1980 Criteria: Data From the Canadian Scleroderma Research Group. Arthritis Care & Research. 2015;67(4):582-587. doi:10.1002/acr.22451
12. Lambova S, Müller-Ladner U. Pulmonary arterial hypertension in systemic sclerosis. Autoimmunity Reviews. 2010;9(11):761-770.
13. Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther. 2003;5(2):80. doi:10.1186/ar628
14. Arason GJ, Geirsson ÁJ, Kolka R, et al. Deficiency of complement-dependent prevention of immune precipitation in systemic sclerosis. Annals of the rheumatic diseases. 2002;61(3):257-260.
15. Gan CT, McCann GP, Marcus JT, et al. NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. European Respiratory Journal. 2006;28(6):1190-1194.
16. Steen V, Medsger TA. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis & Rheumatism. 2003;48(2):516-522. doi:10.1002/art.10775